PET/CT

Item NoDescription
61523Lung – Solitary Pulmonary Nodule
Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
61524Breast Cancer - Staging of locally advanced (Stage III) disease
Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for
a patient who is considered suitable for active therapy
61525Breast Cancer - Suspected metastasis or local/regional recurrence
Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally
or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy
61529Non Small Cell Lung Carcinoma
Whole body FDG PET study, performed for the staging of proven non-small cell
lung cancer, where curative surgery or radiotherapy is planned.
61538Malignant Brain Tumour
FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.
61541Colorectal Carcinoma – Restaging
Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.
61553Melanoma
Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.
61559Epilepsy
FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.
61565Ovarian Carcinoma – Restaging
Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.
61571Carcinoma Uterine Cervix – Staging
Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
61575Carcinoma Uterine Cervix – Restaging
Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.
61577Oesophageal or GEJ Carcinoma
Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy.
61598Head and Neck Cancer – Staging
Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer.
61604Head and Neck Cancer (Residual) – Restaging
Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy.
61610Metastatic SCC Cervical Lymph Nodes – Unknown Primary
Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
61620Lymphoma – Initial Staging
Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin’s or non-Hodgkin’s lymphoma.
61622Lymphoma – Therapy Response
Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin’s or non-Hodgkin’s lymphoma.
61628Lymphoma – Restaging
Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin’s or non-Hodgkin’s lymphoma.
61632Lymphoma – Post Second Line Chemotherapy
Whole body FDG PET study to assess response to second-line chemotherapy when stem cell transplantation is being considered for Hodgkin’s or non-Hodgkin’s lymphoma.
61640Bone or Soft Tissue Sarcoma – Staging
Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.
61646Residual or Recurrent Sarcoma – Restaging
Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.